For Media Inquiries, Please Contact:
Jordan Berman
Vice President,
Global Corporate Communications
Apotex Inc.
150
Signet Drive,
North York,
ON, M9L 1T9
Canada
416-401-7487
Email
Press Center
-
July 20, 2022Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-Apixaban™ tablets, Canada's first generic alternative to Eliquis®
-
May 17, 2022Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the Canadian launch of APO-Teriflunomide™ tablets, a generic version of Aubagio®, for the treatment of relapsing remitting multiple sclerosis (RRMS).
-
April 12, 2022Apotex Corp. announced today its release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane® in the United States.
-
February 2, 2021
-
May 26, 2020
-
May 26, 2020
-
May 25, 2020
-
April 21, 2020
-
April 17, 2020
-
April 13, 2020
-
March 23, 2020
-
March 5, 2020
-
September 20, 2018Melbourne, September 20, 2018 – The Australian Competition and Consumer Commission (ACCC) announced this morning that it ‘has decided not to oppose the merger of generic pharmaceutical companies, Arrow and Apotex’ after finding the transaction would not substantially lessen competition in any market.
-
July 14, 2018Sale Part of Previously Announced Plan to Assess Global Footprint
-
June 1, 2018Health Canada Leads the Way by Approving the First-Ever Pegfilgrastim Biosimilar in any Highly Regulated World Market
-
May 9, 2018Apotex Australia, an affiliate of Apotex Inc., headquartered in Toronto, Canada, today announced a proposed merger of their Australian and New Zealand generic pharmaceutical and over-the-counter (OTC) operations with Arrow Pharmaceuticals.
-
June 12, 2017Apobiologix, a division of the Apotex Group focused on biologics innovation, today announced their support of the Supreme Court decision in the Sandoz v Amgen case. The case clarifies the timing of the Biologics Price Competition and Innovation Act (BPCIA) requiring biosimilar companies to provide 180-days notice to the companies of the reference products of intent to market the biosimilar.
-
June 8, 2017Two Toronto scientists who spearheaded the research that brought a life-saving drug to patients around the world are being honored at the annual Cooley's Anemia Foundation Gala tonight in New York City.
-
April 28, 2017The University of Saskatchewan and Apotex Inc. have renewed their partnership with a $1.6 million donation by the company to the College of Pharmacy and Nutrition.
-
March 8, 2017Today Apotex Inc., the largest Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan
